Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human c-Met that contains tyrosine 1349. The sequence is conserved in mouse and rat.|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.3, with 1mg/ml BSA, 50% glycerol|
|Contains||0.05% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The c-Met oncogene was originally isolated from a chemical carcinogen-treated human osteogenic sarcoma cell line by transfection analysis in NIH/3T3 cells. The Met proto-oncogene product was identified as a trans-membrane receptor-like protein with tyrosine kinase activity that is expressed in many tissues. The c-Met gene product has been identified as the cell surface receptor for hepatocyte growth factor, a plasminogen-like protein thought to be a humoral mediator of liver regeneration.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
44-892G was used in western blot to study c-Met expression and inhibition in a large cohort of renal cell carcinoma tumors and cell lines.
|Gibney GT,Aziz SA,Camp RL,Conrad P,Schwartz BE,Chen CR,Kelly WK,Kluger HM||Annals of oncology : official journal of the European Society for Medical Oncology (24:343)||2013|
MET and phosphorylated MET as potential biomarkers in lung cancer.
44-892G was used in immunohistochemistry to assess expression and prognostic role of the receptor tyrosine kinase MET, phosphorylated MET, and the ligand hepatocyte growth factor in patients with lung cancer.
|Tretiakova M,Salama AK,Karrison T,Ferguson MK,Husain AN,Vokes EE,Salgia R||Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer (30:341)||2011|
c-met; EC 126.96.36.199; Hepatocyte growth factor receptor; Hepatocyte growth factor receptor precursor; HGF receptor; HGF-SF receptor; HGF/SF receptor; kinase EC 188.8.131.52; Met proto- oncogene tyros; Met proto- oncogene tyrosine kinase; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met
AUTS9; c-Met; DFNB97; HGFR; MET; RCCP2